MDMA-AT

The Light of Psychedelics in a Dark World

Rick Doblin reflects on 38 years of MAPS, discussing psychedelic milestones and obstacles. Lykos Therapeutics submits NDA for MDMA-assisted therapy for PTSD in December 2023.

Rick Doblin

PS2023 MDMA MDMA-AT Policy and Advocacy Psychedelic Assisted Therapy PTSD Research

Pioneers of MDMA Therapy: Reflections on 20+ Years of MDMA Therapy and Research

MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.

Keren Tzarfaty, Michael Mithoefer, Julie Holland

PS2023 Healing for All MDMA MDMA-AT Mental Health Psychedelic Assisted Therapy Research and Science

Unlocking the Healing Potential: A Conversation on Experiential Training in MDMA-Assisted Therapy with Payton Nyquvest and Rick Doblin

Payton Nyquvest and Rick Doblin discuss MDMA-Assisted Therapy's transformative potential for healing and mental health in an insightful panel discussion.

PS2023 Health Conditions MDMA MDMA-AT Psychedelic Assisted Therapy PTSD Research and Science

Investigational MDMA-assisted therapy and eating disorder symptoms in a randomized placebo-controlled trial for severe PTSD

MDMA-assisted therapy (MDMA-AT) shows promise in treating PTSD and comorbid eating disorders. A study found significant reductions in eating disorder symptoms with MDMA-AT compared to placebo in severe PTSD patients.

Adele LaFrance, Timothy Brewerton